Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam

Citation
Pmm. Beemsterboer et al., Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam, J UROL, 164(4), 2000, pp. 1216-1220
Citations number
16
Categorie Soggetti
Urology & Nephrology","da verificare
Journal title
JOURNAL OF UROLOGY
ISSN journal
00225347 → ACNP
Volume
164
Issue
4
Year of publication
2000
Pages
1216 - 1220
Database
ISI
SICI code
0022-5347(200010)164:4<1216:PSATAD>2.0.ZU;2-7
Abstract
Purpose: Worldwide 2 large-scale randomized screening trials for prostate c ancer have been initiated. Determining prostate specific antigen (PSA) invo lves a simple test that; may influence the outcome of these trials if frequ ently done in the control arm or before study enrollment. We quantified PSA and digital rectal examination before and during the screening trial in Ro tterdam, The Netherlands and in the general population. Materials and Methods: Trial participants were administered study intake qu estionnaires on tests done before study participation. Data on PSA from the regional general practice laboratory were correlated with participant data . Various sources were used to quantify PSA tests and digital rectal examin ations in the general population. Results: Of men 55 to 74 years old 45% underwent digital rectal examination at 1 time and 13% reported that PSA was tested before trial participation. Each rate increased with age. No statistically significant effect of forme r PSA testing or digital rectal examination on the cancer detection rate wa s identified. The rate of PSA determination after initial screening and/or randomization in the control arm was 2-fold that in the screening arm (76 v ersus 33/1,000 person-years). PSA determination initially decreased in the screening arm but increased rapidly after some time. The number of PSA dete rminations in the general population was estimated to be 45/1,000 person-ye ars at ages 55 to 69 years. Conclusions: PSA testing was moderate in the control arm but if different m en undergo this test each year, the contamination rate may become rather hi gh. In the final analysis of mortality PSA testing should be considered.